Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
05/2003
05/01/2003WO2002070548A3 Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity
05/01/2003WO2002030409A9 Methods for the treatment of a traumatic central nervous system injury
05/01/2003WO2002026224A3 Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
05/01/2003US20030083504 N- (4-carbamimidoyl-phenyl) -glycine derivatives
05/01/2003US20030083500 Imidazonaphthyridines
05/01/2003US20030083363 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
05/01/2003US20030083351 Antihypoxic agents
05/01/2003US20030083325 Serotonin antagonists
05/01/2003US20030083310 Process for producing an iron-dextran compound, iron-dextran compound produced according to said process, pharmaceutical composition for prophylaxis or treatment of iron-deficiency and use of said compound for the preparation of a parenterally administrable pharmaceutical composition
05/01/2003US20030083296 Antisense modulation of caspase 8 expression
05/01/2003US20030083295 An oligonucleotides are hybridizable with nucleic acids to inhibit the gene expression of enzyme
05/01/2003US20030083294 Enhancing or inhibiting the biological activity of nucleic acid ligands by administrating a modulator, to change the binding of the nucleic acid ligand for its target or degrading or cleaving
05/01/2003US20030083272 Sense mrna therapy
05/01/2003US20030083257 Spliceable nucleotide sequence inserted into the wild-type factor viii cDNA at the original position of an intron of the genomic factor viii DNA; gene therapy; treatment of hemophilia
05/01/2003US20030083254 Heparanase-like proteins and nucleotides that encode them
05/01/2003US20030083252 Neuronal uses of BMP-11
05/01/2003US20030083246 Methods for treating rheumatic diseases using a soluble CTLA4 molecule
05/01/2003US20030083233 Aqueous mixtures of oxygen-carrying and non-oxygen carrying plasma expanders; oxygen-carrying component consists of hemoglobin-based oxygen carrier, non-oxygen carrying plasma expander consists of diluent; blood substitutes
05/01/2003US20030082805 Methods for use of mpl ligands with primitive human stem cells
05/01/2003US20030082643 Human monoclonal antibodies to FC alpha receptor (CD89)
05/01/2003US20030082636 Antibody for use as tool in the treatment of blood disorders
05/01/2003US20030082612 Detection of mutant leptin receptor; obtain cells, extract nucleotide sequences, incubate with an oligonucleotide probe, detect hybridization, presence of hybridization, indicates defective receptor
05/01/2003US20030082609 Nuceotide sequences coding polypeptide for use in humans therapeutics and diagnostics
05/01/2003US20030082575 Translation system for use in the generation of protein containing adjusted amino acid sequences
05/01/2003US20030082554 Nucleotide sequences coding polypeptide for use in the treatment of immunlological, thyroid, metabolic, bone and pancreatic disorders
05/01/2003US20030082180 Combination of compounds that inhibit the biological effects of tnf-alpha and cd95l in a medicament
05/01/2003US20030082158 Production of transduced hematopoietic progenitor cells
05/01/2003US20030082105 Selectively targeted fluorescent, radiolabeled, or fluorescent and radiolabeled compositions
05/01/2003CA2466813A1 Benzimidazole derivatives and their use as kdr protein kinase inhibitors
05/01/2003CA2465261A1 Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis
05/01/2003CA2464593A1 6-hydroxy isoflavones, derivatives and medicaments involving same
05/01/2003CA2464344A1 Ee3-protein family and corresponding dna sequences
05/01/2003CA2464290A1 Stents
05/01/2003CA2464085A1 A combination product comprising melagatran and dexamethasone
05/01/2003CA2463772A1 Thrombin-cleavable chimeric proteins
05/01/2003CA2463311A1 Androgen receptor modulators and methods of use thereof
05/01/2003CA2463101A1 Azole derivatives and pharmaceutical compositions containing them
05/01/2003CA2462714A1 Method for preparing heparin from mast cell cultures
04/2003
04/30/2003CN1414965A Sulfonamides and derivatives thereof that modulate the activeity of endothelin
04/30/2003CN1414958A Nonpeptide substituted benzothiazepines as vasopressin antagonists
04/30/2003CN1414956A Substituted piperazine derivatives as MIP inhibitors
04/30/2003CN1414858A Combinations of receptor tyrosine kinase inhibitor with a1-acidic glycoprotein binding organic compound
04/30/2003CN1413724A Brain active effect matter for prevention and curing encephalopathy and developing intelligence and its preparation method
04/30/2003CN1413723A Method for extracting medicine from bluish dogbane
04/30/2003CN1413695A Medicine for treating leukopenia caused by carcinosis radiotherapy and chemotherapy
04/30/2003CN1413679A Medicine for removing obstruction in channels to thrombolytic
04/30/2003CN1413618A Sanweishenxue capsule for treating aplastic anemia and its preparation technology
04/30/2003CN1413609A Chinese medicine composite for treatment and prevention of cerebral arteries obstruction
04/30/2003CN1107058C Subsitituted isoxazoles for treatment of inflammation
04/30/2003CN1106845C Process for preparing solid-state-microspherical vascular cuppository of sodium alginate
04/29/2003US6555575 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
04/29/2003US6555559 5,6,7-trinor-4,8-inter-m-phenylene PGI2, derivative and drugs containing the same
04/29/2003US6555556 N-(4-(1-acetimidoylpiperidin-4-yl)oxyphenyl)-N-((E)-3-(3 -amidinophenyl)-2-methyl-2-propenyl)sulfamoylacetic acid dihydrochloride for example; factor Xa inhibitors
04/29/2003US6555543 Inhibiting the effects of platelet activating factor (PAF).
04/29/2003US6555542 Sulfonamide lactam inhibitors of FXa and method
04/29/2003US6555527 Hematopoietic, myeloprotecting, antitumor immune cells generating and radiosensitizing polysaccharide isolated from Panax ginseng
04/29/2003US6555519 O-glucosylated benzamide SGLT2 inhibitors and method
04/29/2003US6555518 2',2'-difluoronucleosides for suppressing rejection of transplants in mammals; for treatment of autoimmune diseases
04/29/2003US6555377 Process for production of mammalian cell lines
04/29/2003US6555319 Antibodies for inhibiting blood coagulation and methods of use thereof
04/29/2003CA2258502C Modified factor viii
04/29/2003CA2011992C Use of human interferon-beta for stimulation of erythropoiesis
04/25/2003CA2409910A1 Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
04/24/2003WO2003034791A1 Mounting arrangement for auxiliary burner or lance
04/24/2003WO2003033664A2 Bone anti-resorptive compounds
04/24/2003WO2003033527A2 Cyclosporine analogue mixtures and their use as immunomodulating agents
04/24/2003WO2003033522A1 Isolation of lectins
04/24/2003WO2003033502A1 Bicyclic oxopyridine and oxopyrimidine derivatives
04/24/2003WO2003033501A1 Himbacine analogues as thrombin receptor antagonists
04/24/2003WO2003033484A1 Substituted piperazine cyclohexane carboxilic acid amides and the use thereof
04/24/2003WO2003033483A1 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
04/24/2003WO2003033482A1 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors
04/24/2003WO2003033467A1 Nitroso diphenylamine derivatives as nitrogen monoxide generating agents
04/24/2003WO2003033457A1 Biphenyl-derivatives as p38-kinase inhibitors
04/24/2003WO2003033046A2 Blood processing systems and methods that alternate flow of blood component and additive solution through an in-line leukofilter
04/24/2003WO2003033010A1 Cyclosporin analogs for the treatment of autoimmune diseases
04/24/2003WO2003033002A1 Intracellular calcium concentration increase inhibitors
04/24/2003WO2003033001A1 Combinations comprising cox-2 inhibitors and aspirin
04/24/2003WO2003032987A1 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032986A1 2' -methyl-5-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032980A1 5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032971A1 5’-acylamino-1,1’-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032970A1 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032918A2 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors
04/24/2003WO2003032910A2 Carbinols for the treatment of neuropathic dysfunction
04/24/2003WO2003032866A2 Detection and treatment of intravascular lesions
04/24/2003WO2002076509A3 Preparation for the prophylaxis of restenosis
04/24/2003WO2002068406A3 Substituted amine derivatives and their use for the treatment of angiogenesis
04/24/2003WO2002064748A8 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
04/24/2003WO2002046383A3 Protein modification and maintenance molecules
04/24/2003WO2002045431A3 Genetically engineered herpes virus for the treatment of cardiovascular disease
04/24/2003WO2002036798A3 Inhibitors of transglutaminases
04/24/2003WO2002026825A3 G-protein coupled receptors
04/24/2003US20030078438 N-heterocyclicamide compounds; used as anticoagulant agent
04/24/2003US20030078431 Biheterocyclic compounds having high anticoagulant activity, used as inhibitors of factor Xa
04/24/2003US20030078417 For protecting cells from injury due to intrinsic membrane lysis, oxidation and/or invasion by destructive agents; for therapy of phospholipase mediated injury, injury due to oxidation, and inflammation
04/24/2003US20030078280 Macroheterocylic compounds useful as kinase inhibitors
04/24/2003US20030078279 For therapy and prophylaxis of pain, central nervous system disorder or the like in mammalian subjects
04/24/2003US20030078278 Spiropiperidine compounds as ligands for ORL-1 receptor
04/24/2003US20030078270 Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
1 ... 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 ... 671